Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00933309 · ClinicalTrials.gov registry record · Phase 1
The Impact of Obesity and Obesity Treatments on Breast Cancer
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00933309: Completed Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00933309 is a Phase 1 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00933309, a Phase 1 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to find the highest tolerable dose of Avandamet that can be given in combination with exemestane to patients who are obese and postmenopausal with hormone-receptive-positive breast cancer that has spread to other parts of the body.
Interventions
- DRUG Exemestane
- DRUG Avandamet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00933309
The ClinicalTrials.gov registry entry for NCT00933309 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Exemestane is the first listed.
NCT00933309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00933309 about?
NCT00933309 is a clinical study titled "The Impact of Obesity and Obesity Treatments on Breast Cancer". The goal of this clinical research study is to find the highest tolerable dose of Avandamet that can be given in combination with exemestane to patients who are obese and postmenopausal with hormone-receptive-positive breast cancer that has spread to other parts of the body.
What is the current status of trial NCT00933309?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-07. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00933309?
The interventions under investigation include: Exemestane (DRUG), Avandamet (DRUG).
Who is sponsoring clinical trial NCT00933309?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.